Systemic RAGE ligands are upregulated in tuberculosis individuals with diabetes co-morbidity and modulated by anti-tuberculosis treatment and metformin therapy

Impact of Diabetes Mellitus on Treatment Outcomes of Patients with Active Tuberculosis

(2018) Kelly E. Dooley et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment

(2018) Nathella P. Kumar et al.   BMC INFECTIOUS DISEASES

A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug?

(2017) Kunal Maniar et al.   PHARMACOLOGICAL RESEARCH

Systems Immunology of Diabetes-Tuberculosis Comorbidity Reveals Signatures of Disease Complications

(2017) Cesar A. Prada-Medina et al.   Scientific Reports

High Prevalence and Heterogeneity of Diabetes in Patients With TB in South India

(2016) Hardy Kornfeld et al.   CHEST

Tuberculosis and diabetes: current state and future perspectives

(2016) Damiano Pizzol et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

S100A12 is up-regulated in pulmonary tuberculosis and predicts the extent of alveolar infiltration on chest radiography: an observational study

(2016) Luis C. Berrocal-Almanza et al.   Scientific Reports

HMGB1/RAGE Signaling and Pro-Inflammatory Cytokine Responses in Non-HIV Adults with Active Pulmonary Tuberculosis

(2016) Grace Lui et al.   PLoS One

Plasma HMGB-1 Levels in Subjects with Obesity and Type 2 Diabetes: A Cross-Sectional Study in China

(2015) Hang Wang et al.   PLoS One

Impact of diabetes on the natural history of tuberculosis

(2014) Blanca I. Restrepo et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Diabetes and immunity to tuberculosis

(2014) Nuria Martinez et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Metformin as adjunct antituberculosis therapy

(2014) A. Singhal et al.   Science Translational Medicine

S100A8/A9 Proteins Mediate Neutrophilic Inflammation and Lung Pathology during Tuberculosis

(2013) Radha Gopal et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

The double burden of diabetes and tuberculosis – Public health implications

(2013) Anil Kapur et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Global confluence of infectious and non-communicable diseases — The case of type 2 diabetes

(2013) M.J. Magee et al.   PREVENTIVE MEDICINE

Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania

(2013) Daniel Faurholt-Jepsen et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Evaluation of High-Mobility Group Box 1 Protein Concentration in Serum of Patients withM. tuberculosisInfection

(2012) Agnieszka Magryś et al.   IMMUNOLOGICAL INVESTIGATIONS

Receptor for advanced glycation end products is protective during murine tuberculosis

(2012) Marieke A.D. van Zoelen et al.   MOLECULAR IMMUNOLOGY

Non-Diabetic Hyperglycemia Exacerbates Disease Severity in Mycobacterium tuberculosis Infected Guinea Pigs

(2012) Brendan K. Podell et al.   PLoS One

Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications

(2011) Ravichandran Ramasamy et al.   Annals of the New York Academy of Sciences

The impact of diabetes on tuberculosis treatment outcomes: A systematic review

(2011) Meghan A Baker et al.   BMC Medicine

Heparan Sulfate Is Essential for High Mobility Group Protein 1 (HMGB1) Signaling by the Receptor for Advanced Glycation End Products (RAGE)

(2011) Ding Xu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

RAGE: The beneficial and deleterious effects by diverse mechanisms of actions

(2011) Sun-Ho Han et al.   MOLECULES AND CELLS

Lack of the Receptor for Advanced Glycation End-Products Attenuates E. coli Pneumonia in Mice

(2011) Lasse Ramsgaard et al.   PLoS One

Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome

(2010) Anastassios C Manolakis et al.   BMC GASTROENTEROLOGY

The Receptor for Advanced Glycation End Products (RAGE) and the Lung

(2010) Stephen T. Buckley et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Advanced glycation end products induce the expression of interleukin-6 and interleukin-8 by receptor for advanced glycation end product-mediated activation of mitogen-activated protein kinases and nuclear factor- B in human osteoarthritis chondrocytes

(2010) Z. Rasheed et al.   RHEUMATOLOGY

Structural Basis for Ligand Recognition and Activation of RAGE

(2010) Michael Koch et al.   STRUCTURE

Hyperglycemia-Induced Reactive Oxygen Species Increase Expression of the Receptor for Advanced Glycation End Products (RAGE) and RAGE Ligands

(2009) D. Yao et al.   DIABETES

Advanced glycation end products and lipopolysaccharide synergistically stimulate proinflammatory cytokine/chemokine production in endothelial cells via activation of both mitogen-activated protein kinases and nuclear factor-κB

(2009) Jinghua Liu et al.   FEBS Journal

Tuberculosis and diabetes mellitus: convergence of two epidemics

(2009) Kelly E Dooley et al.   LANCET INFECTIOUS DISEASES

Human S100A12: a novel key player in inflammation?

(2008) Jens Pietzsch et al.   AMINO ACIDS

Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis

(2008) C. S. WANG et al.   EPIDEMIOLOGY AND INFECTION

Diabetes Mellitus Increases the Risk of Active Tuberculosis: A Systematic Review of 13 Observational Studies

(2008) Christie Y Jeon et al.   PLOS MEDICINE

S100A12 protein is a strong inducer of neurite outgrowth from primary hippocampal neurons

(2003) Sanne E. Mikkelsen et al.   JOURNAL OF NEUROCHEMISTRY